Xénia Gonda

2 papers in the library · 77 citations · publishing 2021-2026

Papers

Novel antidepressant drugs: Beyond monoamine targets

CNS Spectrums September 30, 2021 Xénia Gonda, Péter Döme, Joanna C. Neill et al. 77 citations

Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain inadequately addressed by current antidepressants, which have limited efficacy or undesirable side effects linked to their actions on monoamine neurotransmitters (serotonin, norepinephrine, dopamine). New drugs targeting non-monoamine pathways, such as the recently approved intranasal Esketamine (a glutamatergic agent) combined with an oral antidepressant for adult TRD, offer promise. Several glutamatergic and GABAergic drugs are in clinical development, and preliminary positive trial results with psychedelics like psilocybin, Ayahuasca, 5-MeO-DMT, and LSD suggest they may become effective therapies. Expanding beyond monoamine targets appears to yield antidepressants with superior efficacy, safety, and tolerability.

DOI: 10.1017/s1092852921000791 Major depressive disorder Antidepressant Monoamine neurotransmitter Tolerability +5

Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology July 17, 2026 Mauro Scala, Enrico Magrini, Ivana Leccisotti et al.

Suicide remains a leading cause of early death worldwide, and current treatments are limited by slow onset, short durability, or poor tolerability. This narrative review of 34 studies over the past decade examined pharmacological and neuromodulation interventions for suicidal ideation or suicide attempt that are not yet approved for these uses. Across controlled trials, suicidal ideation commonly improved within days to weeks. Some trials reported reductions in suicidal ideation beyond changes in depression scores, suggesting partial independence, though evidence remains inconsistent. Encouraging results were reported for NMDA-related drugs, opioid-system modulation, ayahuasca, and certain neuromodulation techniques, while non-medical cannabis use was associated with worse suicidal ideation trajectories.

DOI: 10.1016/j.euroneuro.2026.112888 Full text N-methyl-d-aspartate receptor antagonists Neuromodulation Opioid agonists Suicidal ideation +2